PH12016500371B1 - Stable polypeptides binding to human complement c5 - Google Patents

Stable polypeptides binding to human complement c5

Info

Publication number
PH12016500371B1
PH12016500371B1 PH12016500371A PH12016500371A PH12016500371B1 PH 12016500371 B1 PH12016500371 B1 PH 12016500371B1 PH 12016500371 A PH12016500371 A PH 12016500371A PH 12016500371 A PH12016500371 A PH 12016500371A PH 12016500371 B1 PH12016500371 B1 PH 12016500371B1
Authority
PH
Philippines
Prior art keywords
human complement
polypeptides binding
stable polypeptides
stable
binding
Prior art date
Application number
PH12016500371A
Other languages
English (en)
Other versions
PH12016500371A1 (en
Inventor
Joakim Nilsson
Erik Nordling
Patrik Str™Mberg
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Publication of PH12016500371A1 publication Critical patent/PH12016500371A1/en
Publication of PH12016500371B1 publication Critical patent/PH12016500371B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
PH12016500371A 2013-08-28 2016-02-24 Stable polypeptides binding to human complement c5 PH12016500371B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1350986 2013-08-28
PCT/EP2014/068282 WO2015028558A1 (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5

Publications (2)

Publication Number Publication Date
PH12016500371A1 PH12016500371A1 (en) 2016-05-02
PH12016500371B1 true PH12016500371B1 (en) 2016-05-02

Family

ID=51539238

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016500371A PH12016500371B1 (en) 2013-08-28 2016-02-24 Stable polypeptides binding to human complement c5

Country Status (29)

Country Link
US (1) US9994626B2 (https=)
EP (2) EP3811961B1 (https=)
JP (2) JP6767865B2 (https=)
KR (1) KR102446636B1 (https=)
CN (1) CN105658228B (https=)
AU (1) AU2014314222B2 (https=)
BR (1) BR112016003142A2 (https=)
CA (1) CA2926976C (https=)
CY (1) CY1123732T1 (https=)
DK (1) DK3038633T3 (https=)
ES (1) ES2842105T3 (https=)
HR (1) HRP20210013T1 (https=)
HU (1) HUE052613T2 (https=)
IL (1) IL244218A (https=)
LT (1) LT3038633T (https=)
MX (1) MX382140B (https=)
MY (1) MY173804A (https=)
NZ (1) NZ718153A (https=)
PH (1) PH12016500371B1 (https=)
PL (1) PL3038633T3 (https=)
PT (1) PT3038633T (https=)
RS (1) RS61347B1 (https=)
RU (2) RU2020128977A (https=)
SA (1) SA516370622B1 (https=)
SG (1) SG11201602679VA (https=)
SI (1) SI3038633T1 (https=)
SM (1) SMT202100006T1 (https=)
UA (1) UA117933C2 (https=)
WO (1) WO2015028558A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3511339B1 (en) * 2012-02-20 2025-04-09 IPC Research, LLC Polypeptides binding to human complement c5
MX367423B (es) * 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
BR112016003142A2 (pt) * 2013-08-28 2017-10-17 Swedish Orphan Biovitrum Ab Publ ligação de polipeptídeos estáveis ao c5 do complemento humano
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
KR102806328B1 (ko) 2017-07-11 2025-05-14 알렉시온 파마슈티칼스, 인코포레이티드 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질
EP4291251B1 (en) * 2021-02-15 2025-02-19 Affibody AB Her2-binding polypeptide
JP2024540351A (ja) * 2021-11-01 2024-10-31 アイピーシー・リサーチ・エルエルシー C5結合タンパク質の投与
WO2024227886A1 (en) 2023-05-02 2024-11-07 Mebrahtu Aman Bispecific binding molecule

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
EP2896631A1 (en) 2000-10-10 2015-07-22 Genentech, Inc. Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
ES2283594T5 (es) 2001-08-17 2016-03-15 Genentech, Inc. Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
CA2579635A1 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
NZ571791A (en) * 2006-03-08 2012-03-30 Archemix Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
EP2190863B1 (en) 2007-07-31 2015-09-02 Affibody AB New albumin binding compositions, methods and uses
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
ES2373832T3 (es) * 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
CN103003296A (zh) * 2010-07-09 2013-03-27 阿菲博迪公司 多肽
EP3511339B1 (en) * 2012-02-20 2025-04-09 IPC Research, LLC Polypeptides binding to human complement c5
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
JP6577868B2 (ja) 2012-12-19 2019-09-18 アフィボディ・アーベー 新規ポリペプチド
BR112016003142A2 (pt) * 2013-08-28 2017-10-17 Swedish Orphan Biovitrum Ab Publ ligação de polipeptídeos estáveis ao c5 do complemento humano
MX367423B (es) * 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.

Also Published As

Publication number Publication date
RU2733897C2 (ru) 2020-10-09
CA2926976C (en) 2023-11-28
SMT202100006T1 (it) 2021-03-15
AU2014314222A1 (en) 2016-04-21
SI3038633T1 (sl) 2021-05-31
RU2020128977A (ru) 2021-11-30
HUE052613T2 (hu) 2021-05-28
EP3811961A1 (en) 2021-04-28
RU2016111115A (ru) 2017-10-03
PH12016500371A1 (en) 2016-05-02
CA2926976A1 (en) 2015-03-05
IL244218A0 (en) 2016-04-21
PT3038633T (pt) 2021-01-14
CY1123732T1 (el) 2021-10-29
UA117933C2 (uk) 2018-10-25
IL244218A (en) 2017-11-30
RU2016111115A3 (https=) 2018-04-25
BR122023020080A2 (pt) 2023-12-26
SA516370622B1 (ar) 2018-12-23
US9994626B2 (en) 2018-06-12
JP6767865B2 (ja) 2020-10-14
EP3038633B1 (en) 2020-10-14
MY173804A (en) 2020-02-24
EP3038633A1 (en) 2016-07-06
DK3038633T3 (da) 2021-01-11
HRP20210013T1 (hr) 2021-04-02
EP3811961B1 (en) 2025-08-20
ES2842105T3 (es) 2021-07-12
US20160311870A1 (en) 2016-10-27
CN105658228A (zh) 2016-06-08
AU2014314222B2 (en) 2018-05-24
BR112016003142A2 (pt) 2017-10-17
KR20160048121A (ko) 2016-05-03
NZ718153A (en) 2022-05-27
SG11201602679VA (en) 2016-05-30
RS61347B1 (sr) 2021-02-26
LT3038633T (lt) 2021-03-25
WO2015028558A1 (en) 2015-03-05
JP2016529270A (ja) 2016-09-23
MX2016002397A (es) 2016-09-08
HK1225656A1 (en) 2017-09-15
JP2020172505A (ja) 2020-10-22
MX382140B (es) 2025-03-13
PL3038633T3 (pl) 2021-07-19
KR102446636B1 (ko) 2022-09-23
CN105658228B (zh) 2020-02-07

Similar Documents

Publication Publication Date Title
PH12016500371B1 (en) Stable polypeptides binding to human complement c5
SA519410284B1 (ar) Cd3 بنيات بولي ببتيد متعددة النوعية ذات ربط ل مقيد وطرق لاستخدامها
PH12018501882A1 (en) Binding proteins and methods of use thereof
PH12019500600A1 (en) Antibodies against signal-regulatory protein alpha and methods of use
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
MY187827A (en) New polypeptide having affinity to pd-l1
MY200609A (en) Antibodies binding to vista at acidic ph
MY209489A (en) Antibody against human il-4ra and use thereof
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MY188784A (en) Il-17a-binding polypeptides
MY191944A (en) Binding proteins and methods of use thereof
MX2019011952A (es) Proteina anti-garp y sus usos.
WO2015073884A3 (en) Glycoengineered antibody compositions
IL270951A (en) Polypeptides binding adamts5, mmp13 and aggrecan
EP3705494A3 (en) Antibodies against frizzled proteins and methods of use thereof
PH12015501854A1 (en) Factor ix polypeptide formulations
WO2016023898A3 (en) Intracellular antigen binding
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
MX2021010021A (es) Proteínas sintéticas autoensamblables.
NZ757598A (en) Il-1r-i binding polypeptide
EP4512469A3 (en) Binding proteins to the human thrombin receptor, par4
MX2018011193A (es) Proteinas derivadas de alfa-1-microglobulina novedosas y su uso.
TR201908753T4 (tr) Bi̇r prosteti̇k soket i̇le bi̇r prosteti̇k uzuv arasinda bağlanti parçasi